(Total Views: 496)
Posted On: 03/21/2025 11:45:48 AM
Post# of 155854
Group/Sub-group:
Feb. 24, 2025 : "...today announced encouraging survival outcomes among a group of patients with metastatic triple-negative breast cancer (“mTNBC”) ..."
March 18, 2025: "...Of particular interest, we identified a subgroup of these patients..."
" The exciting observation of improved survival in patients with mTNBC treated with leronlimab has naturally prompted us to reframe the focus of our oncology manuscripts. Submission of these oncology manuscripts for peer review is a top publication priority."
There's more to our Oncology transcript then the March news released. Trodelvy was approved on markers showing --- a likely future shrinkage of tumors.
Well, ummmm....March 18th, 2025.
We're qualified for an FDA approval.
Feb. 24, 2025 : "...today announced encouraging survival outcomes among a group of patients with metastatic triple-negative breast cancer (“mTNBC”) ..."
March 18, 2025: "...Of particular interest, we identified a subgroup of these patients..."
" The exciting observation of improved survival in patients with mTNBC treated with leronlimab has naturally prompted us to reframe the focus of our oncology manuscripts. Submission of these oncology manuscripts for peer review is a top publication priority."
There's more to our Oncology transcript then the March news released. Trodelvy was approved on markers showing --- a likely future shrinkage of tumors.
Well, ummmm....March 18th, 2025.
We're qualified for an FDA approval.
(7)
(0)
